Legend Biotech stock price target lowered to $54 at UBS on growth concerns

UBS has lowered its price target on Legend Biotech (LEGN) to $54.00 from $60.00, while maintaining a Buy rating, noting that significant upside hinges on a material acceleration in Carvykti revenue and clearer future revenue goals from management. Despite the price target adjustment, the company has demonstrated 112% LTM revenue growth, and other firms like H.C. Wainwright and RBC Capital continue to hold Buy/Outperform ratings, citing strong long-term clinical data for Carvykti and recent FDA approval easing adoption restrictions, underscoring the therapy's ongoing potential.

Analysis

Legend Biotech (LEGN) presents a narrative of near-term execution uncertainty weighed against significant long-term potential. UBS has tempered its outlook by reducing the price target to $54 from $60, citing the need for a "material step-up" in revenue from the company's cell therapy, Carvykti, with meaningful acceleration not expected until the second half of 2025. This view is supported by the stock's modest 4% year-to-date gain and the potential for range-bound trading. A key ambiguity for investors, as highlighted by UBS, is the unclear translation of the company's goal of 10,000 annualized Carvykti doses into a precise revenue figure. However, this cautious stance is counterbalanced by several potent fundamental tailwinds. The company has posted impressive 112% revenue growth over the last twelve months. Furthermore, recent clinical data from the CARTITUDE-1 study demonstrated compelling long-term efficacy, with one-third of myeloma patients remaining progression-free for over five years after a single infusion. This is complemented by a favorable regulatory development, as the FDA has approved an sBLA that eases monitoring requirements and restrictions, potentially accelerating U.S. adoption. Other analyst firms, including H.C. Wainwright, RBC Capital, and BMO Capital, maintain Buy or Outperform ratings, underscoring a broader market belief in the therapy's strong positioning and the stock's undervaluation.

Key Decisions for Investors

• Investors should weigh the near-term execution risk, reflected by UBS's price target reduction, against the company's robust 112% LTM revenue growth and compelling long-term clinical data for Carvykti.
• Monitor management's future communications closely for clearer revenue guidance for late 2025 or 2026, as this would resolve a key uncertainty and serve as a primary catalyst for the stock.
• Consider the recent positive FDA ruling that eases Carvykti's administration as a significant tailwind that could accelerate adoption and revenue growth, potentially offsetting the short-term concerns raised by UBS.